Vivos Therapeutics (VVOS)
(Delayed Data from NSDQ)
$2.93 USD
-0.15 (-4.87%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $3.10 +0.17 (5.80%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMVivos Therapeutics, Inc. (VVOS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.60 | $6.60 | $6.60 | 114.29% |
Price Target
Only one analyst offered a short-term price target of $6.60 for Vivos Therapeutics, Inc. This represents an increase of 114.29% from the last closing price of $3.08.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Buy-equivalent recommendation for Vivos Therapeutics, Inc. This translates to an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 2.00 a month ago based on just one Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | NA | NA |
Buy | 1 | 1 | 1 | NA | NA |
Hold | 0 | 0 | 0 | NA | NA |
Sell | 0 | 0 | 0 | NA | NA |
Strong Sell | 0 | 0 | 0 | NA | NA |
ABR | 2.00 | 2.00 | 2.00 | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/20/2024 | Ascendiant Capital Markets | Lucas Ward | Not Available | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 1 |
Average Target Price | $6.60 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | NA |